This is a routine board appointment with no immediate trading implications. Monitor for any future strategic shifts that may arise from Ms. Gilson's biotech and M&A background, but no action warranted.
Price Chart
Executive Summary
Rani Therapeutics appointed Michelle Gilson to its Board of Directors and as chair of the Audit Committee, effective August 1, 2026. Ms. Gilson brings recent CFO experience from Arcellx (acquired by Gilead) and a background in biotech equity research. This is a routine board appointment with no material financial impact.
Key Facts
- Michelle Gilson appointed to the Board of Directors and as chair of the Audit Committee, effective August 1, 2026.
- Ms. Gilson served as CFO of Arcellx, Inc. from May 2022 through its acquisition by Gilead Sciences in April 2026.
- She previously worked as a Senior Biotechnology Equity Research Analyst at Canaccord Genuity and held roles at Jefferies, Nomura, Oppenheimer, and Goldman Sachs.
- Compensation will follow the company's standard Non-Employee Director Compensation Policy.
- No arrangements, family relationships, or material interests requiring disclosure exist between Ms. Gilson and the company.
Financial Impact
No financial figures disclosed; director compensation is per standard policy.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-331594 |
| Document: 0001193125-26-331594-index-headers.html | 0001193125-26-331594 |
| Document: 0001193125-26-331594-index.html | 0001193125-26-331594 |
| Document: 0001193125-26-331594.txt | 0001193125-26-331594 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $0.8200 $0.8645 | ▲ +5.43% | ▲ +6.66% | $0.5857 (−28.57%) |
Jul 15, 2026 14w ago | Press Release | $0.6770 $0.8028 | ▲ +18.58% | ▲ +16.24% | $0.5857 (−13.49%) |
May 15, 2026 23w ago | Press Release | $0.9720 $0.7597 | ▼ −21.84% | ▼ −23.42% | $0.5857 (−39.74%) |
Mar 26, 2026 30w ago | Press Release | $0.8110 $0.8900 | ▲ +9.74% | ▼ −3.00% | $0.5857 (−27.78%) |
Mar 19, 2026 31w ago | Press Release | $1.13 $0.9740 | ▼ −13.81% | ▼ −23.12% | $0.5857 (−48.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers